NASDAQ:ITRM Iterum Therapeutics (ITRM) Stock Price, News & Analysis $0.74 -0.01 (-0.80%) Closing price 04:00 PM EasternExtended Trading$0.76 +0.02 (+2.28%) As of 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Iterum Therapeutics Stock (NASDAQ:ITRM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Iterum Therapeutics alerts:Sign Up Key Stats Today's Range$0.73▼$0.7850-Day Range$0.69▼$1.1352-Week Range$0.66▼$3.02Volume623,818 shsAverage Volume601,633 shsMarket Capitalization$33.23 millionP/E RatioN/ADividend YieldN/APrice Target$9.00Consensus RatingBuy Company Overview Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland. Read More Iterum Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreITRM MarketRank™: Iterum Therapeutics scored higher than 38% of companies evaluated by MarketBeat, and ranked 720th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingIterum Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageIterum Therapeutics has received no research coverage in the past 90 days.Read more about Iterum Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Iterum Therapeutics is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Iterum Therapeutics is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.76% of the float of Iterum Therapeutics has been sold short.Short Interest Ratio / Days to CoverIterum Therapeutics has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Iterum Therapeutics has recently increased by 13.04%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIterum Therapeutics does not currently pay a dividend.Dividend GrowthIterum Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.76% of the float of Iterum Therapeutics has been sold short.Short Interest Ratio / Days to CoverIterum Therapeutics has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Iterum Therapeutics has recently increased by 13.04%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 3 news articles for Iterum Therapeutics this week, compared to 1 article on an average week.Search Interest6 people have searched for ITRM on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Iterum Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Iterum Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $10,800.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.40% of the stock of Iterum Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 9.21% of the stock of Iterum Therapeutics is held by institutions.Read more about Iterum Therapeutics' insider trading history. Receive ITRM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Iterum Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ITRM Stock News HeadlinesIterum Therapeutics PLC (NASDAQ:ITRM) Director Michael W. Dunne Purchases 15,000 SharesAugust 13, 2025 | insidertrades.comIterum Therapeutics PLC: Iterum Therapeutics launches ORLYNVAH, the first and only oral penem antibiotic in the U.S.August 20 at 5:12 PM | finanznachrichten.deEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.August 22 at 2:00 AM | Timothy Sykes (Ad)Iterum Therapeutics announces U.S. commercial launch of ORLYNVAHAugust 20 at 5:12 PM | msn.comIterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S.August 20 at 8:00 AM | globenewswire.comIterum Therapeutics (NASDAQ:ITRM) Cut to "Sell" at Wall Street ZenAugust 12, 2025 | americanbankingnews.comIterum Therapeutics plc (NASDAQ:ITRM) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | msn.comITRM Reports ResultsAugust 5, 2025 | fool.comSee More Headlines ITRM Stock Analysis - Frequently Asked Questions How have ITRM shares performed this year? Iterum Therapeutics' stock was trading at $1.77 at the start of the year. Since then, ITRM shares have decreased by 58.0% and is now trading at $0.7440. How were Iterum Therapeutics' earnings last quarter? Iterum Therapeutics PLC (NASDAQ:ITRM) announced its earnings results on Tuesday, August, 5th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.13) by $0.03. Read the conference call transcript. When did Iterum Therapeutics' stock split? Iterum Therapeutics shares reverse split on the morning of Thursday, August 18th 2022.The 1-15 reverse split was announced on Thursday, August 18th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Iterum Therapeutics IPO? Iterum Therapeutics (ITRM) raised $80 million in an initial public offering (IPO) on Friday, May 25th 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. Leerink Partners and RBC Capital Markets served as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers. Who are Iterum Therapeutics' major shareholders? Top institutional shareholders of Iterum Therapeutics include Jane Street Group LLC (0.21%). Insiders that own company stock include Michael W Dunne, Corey N Fishman, Brenton Karl Ahrens and Sailaja Puttagunta. View institutional ownership trends. How do I buy shares of Iterum Therapeutics? Shares of ITRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Iterum Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Iterum Therapeutics investors own include NVIDIA (NVDA), Onconova Therapeutics (ONTX), Zoom Communications (ZM), Tesla (TSLA), Meta Platforms (META), SNDL (SNDL) and Atossa Genetics (ATOS). Company Calendar Last Earnings8/05/2025Today8/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ITRM CIK1659323 Webwww.iterumtx.com Phone(531) 669-4820FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Price Target for Iterum Therapeutics$9.00 High Price Target$9.00 Low Price Target$9.00 Potential Upside/Downside+1,109.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($0.85) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$24.77 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-65.01% Debt Debt-to-Equity RatioN/A Current Ratio2.69 Quick Ratio2.52 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.09) per share Price / Book-8.27Miscellaneous Outstanding Shares44,660,000Free Float43,585,000Market Cap$33.23 million OptionableNot Optionable Beta2.85 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:ITRM) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iterum Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Iterum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.